Breast cancer: Cell and gene therapy

Cancer Investigation

Volumn 15, Issue 6, 1997, Pages 568-576

  Lebkowski, Jane S ^a   Philip, Ramila ^a   Okarma, Thomas B ^a  

^a Applied Immune Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ANTHRACYCLINE; CD34 ANTIGEN; CD8 ANTIGEN; COLCHICINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GAMMA INTERFERON; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; LIPOSOME; PACLITAXEL; SCATTER FACTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VACCINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; BREAST CANCER; CELL TRANSPLANTATION; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0031471455     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709047599     Document Type: Review

References (87)

1. Harris JR, Morrow M, Bonadonng, et al: Cancer of the breast in Cancer: Principles and Practice of Oncology, 4th ed, edited by V DeVita, S Hellman, SA Rosenberg, Philadelphia, JB Lippincott, 1993, pp 1264-1332.
2. Vaughan WP: Autologous bone marrow transplantation in the treatment of breast cancer: Clinical and technologic strategies. Semin Oncol 20(5):55-58, 1993.
3. Fields KK, Elfenbein GJ, Perkins JB, et al: Two novel high-dose treatment regimens for metastatic breast cancer-ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: Outcomes and toxicities. Semin Oncol 20(5):59-66, 1993.
4. Jones RB, Shpall EJ, Shogan J, et al: Intensive induction chemotherapy for metastatic breast cancer. Cancer 66:431-436, 1990.
5. Bell AJ, Hamblin TJ, Oscier DG: Peripheral blood stem cell autografting. Hematology 5:45-55, 1987.
6. Siena S, Bregni M, Brando B, et al: Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74(6):1905-1914, 1989.
7. Socinski MA, Cannistra SA, Elias A, et al: GM-CSF expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1:1194-1198, 1988.
8. Duhrsen U, Villeval JL, Boyd J, et al: Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074-2081, 1988.
9. Villeval JL, Duhrsen U, Morstyn G, et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on progenitor cells in patients with advanced malignancy. Br J Haematol 74:36-44, 1990.
10. Gianni AM, Siena S, Bregni M, et al: Granulocyte-macrophage ' colony-stimulating factor to harvest circulating hematopoietic stem cells for autotransplantation. Lancet 2:580-584, 1989.
11. Brugger W, Bross KJ, Frisch J, et al: Mobilization of peripheral blood progenitor cells by sequential administration of IL-3 and GM-CSF following chemotherapy with etoposide, ifoside, itosfamide, and cisplatin. Blood 79:1193-1200, 1992.
12. Pettengell R, Demuynck H, Testa NG, et al. The engraftment capacity of peripheral blood progenitor cells mobilized with chemotherapy ± G-CSF. Int J Cell Clon 10:59, 1992.
13. Elias AD, Ayash L, Anderson KC, et al: Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 79(11):3036-3044, 1992.
14. Brugger W, Birken R, Bertz H, et al: Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br J Haematol 84:402-407, 1993.
15. Moss TJ, Ross AA: The risk of tumor cell contamination m peripheral blood stem cell collections. J Hematother 1:225-232, 1992.
16. Ross AA, Cooper BW, Lazarus HM, et al: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82(9):2605-2610, 1993.
17. Shpall EJ, Jones RB: Release of tumor cells from bone marrow. Blood 83(3):623-625, 1994.
18. Brugger W, Bross KJ, Glatt M, et al: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83(3):636-640, 1994.
19. Rill DR, Santana VM, Roberts WM, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84(2):380-383, 1994.
20. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83(10):3068-3076, 1994.
21. Shpall EJ, Jones RB, Bast RC, et al: 4-Hydroperoxycyclo-phosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: A phase I trial. J Clin Oncol 9(1):85-93, 1991.
22. Shpall EJ, Anderson IC, Bast RC. et al: Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Bone Marrow Purg Process 321-336, 1990.
23. Shpall EJ, Stemmer SM, Johnston CF, et al: Purging of autologous bone marrow for transplantation: The protection and selection of the hematopoietic progenitor cell. J Hematother 1:45-54, 1992.
24. + marrow cells in patients with breast cancer or neuroblastoma. Blood 77(8):1717-1722, 1991.
25. Shpall EJ, Jones RB, Bearman SI, et al: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose therapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12(1):28-36, 1994.
26. + and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 84(5):1421-1426, 1994.
27. Lebkowski JS, Schain LR, Okrongly D, et al: Rapid isolation of human CD34 hematopoietic stem cells-purging of human tumor cells. Transplantation 53(5): 1011-1019, 1992.
28. + cells into the myeloid lineage. Blood 80(6): 1405-1412, 1992.
29. + progenitor cells by stem cell factor, interleukin-1β (IL-1β), IL-6, IL-3, interferon-β, and erythropoietin. Blood 81(10):2579-2584, 1993.
30. Koller MR, Emerson SG, Palsson BO: Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures. Blood 82(2):378-384, 1993.
31. Rummel SA, Van Zant G: Future paradigm for autologous bone marrow transplantation: Tumor purging and ex vivo production of normal stem and progenitor cells. J Hematother 3:213-218, 1994.
32. +-selected human peripheral blood progenitor cells. Blood 84(9):2898-2903, 1994.
33. + cells. Blood Cells 20:404-410, 1994.
34. + hematopoietic stem cells. J Hematother 2:339-342, 1993.
35. + cells from patients with stage IV breast cancer. Blood 84(10):3567-3574, 1994.
36. Cassel A, Cotter-Fox M, Doren S, et al: Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp Hematol 21:585-591, 1993.
37. Bregni M, Magni M, Siena S, et al: Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood 80:1418-1422, 1992.
38. Moore DE, Deisseroth AB, Reading CL, et al: Stromal support enhanced cell-free retroviral vector transduction of human bone marrow long-term culture-initiating cells. Blood 79:1393-1399, 1992.
39. + cells purified from peripheral blood of breast cancer patients primed with chemotherapy and granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 5:203-208, 1994.
40. Von Kalle C, Kiem HP, Goehle S, et al: Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood. 84(9):2890-2897, 1994.
41. R-transduced bone marrow and peripheral blood stem cells in patients with metastic breast cancer. Hum Gene Ther 4:331-354, 1993.
42. + marrow and peripheral blood cells in patients with multiple myeloma or breast cancer. Blood 82(10)Suppll:217a, 1993.
43. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Med 42:277-286, 1991.
44. DelaFlor-Weiss E, Richardson C, Ward M, et al: Transfer and expansion of the human multidrug resistance gene in mouse erythroleukemia cells. Blood 80(12):3106-3111, 1992.
45. Guild BC, Mulligan RC, Gros P, et al: Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Natl Acad Sci USA 85:1595-1599, 1988.
46. Pastan I, Gottesman MM, Ueda K. et al: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 5:4486-4490, 1988.
47. Mickisch GH, Aksentijevich I, Schoenlein PV, et al: Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 79(4):1087-1093, 1992.
48. Sorrentino BP, Brandt SJ, Bodine D, et al: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257:99-103, 1992.
49. Podda S, Ward M, Himelstein A, et al: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 89:9676-9680, 1992.
50. Hanania EG, Fu S, Roninson I, et al: Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-I transcription unit. Gene Ther 2:1-6, 1995.
51. + cells. Blood 84(5): 1408-1414, 1994.
52. Hanania EG, Fu S, Zu Z. et al: Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther 2:1-10, 1995.
53. Fearon ER, Pardoll DM, Itaya T. et al: Interleukin-2 pruduction by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397-403, 1990.
54. Gansbucher B, Zier K, Daniels B. et al: Interleukin 2 gene transfer into tumor cells tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224, 1990.
55. Gansbacher B, Bannerji R, Daniels B, et al: Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lusting antitumor immunity. Cancer Res 50:7820-7825, 1990.
56. Watanabe Y, Koribayashi K, Miyatake S, et al: Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells: Results in reduced tumorigenicity by augtaunted anti-tumor immunity. Proc Natl Acad Sci USA 86:9456-9458, 1989.
57. + T cells against wild-type tumor: Correlation with antigen presentation capability. J Exp Mad 175:1423-1431, 1992.
58. Golumhek PT, Lazenby A J, Levitzky HI, et al: Treatment of established renal cancer engineered to secrete interieukin-4. Science 2:713-716, 1991.
59. Porgador A, Tzehoval E, Katz A, et al: Interleukin 6 gene transfection into Lewis lung carcinmna tumor cells suppresses the malignant metastatic cells Cancer Res 52:3679-3686, 1992.
60. Blankenstein T, Qin Z, Uherla K, et al: Tumor suppression after tumor cell-targeted tumor necixmis factor oc gene transfer. J Exp Mud 173:1047-1052, 1991.
61. Ohe Y, Fudeck ER, Olsen KJ, et al: Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune isponse against Lewis lung carcinoma cells. Int J Cancer 53:432-437, 1993.
62. Porpdor A, Gunsbacher B, Bunnerji R, et al: And-metastatic vaccination of tumor-hearing mice with IL-2-gnne-inserted tumor cells. Int J Cancer 53:471-477, 1993.
63. Dranoff G, Jaffne E, Lazonby A, et al: Vaccination with irradiated tumor cells engineered to secrete routine granulocyte-macrophage colony-stimulating factor stimulated potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543, 1993.
64. Coonor J, Bannerji R, Salto S, et al: Regression of bladder tumors in mice treated with intefieukin 2 gene-modified tumor cells. J Exp Med 177:1127-1134, 1993.
65. Rosenthal FM, Cronin K, Bannerji R, et al: Augmentation of anti-tumor immunity by tumor cells transduced with a relviral vactor carrying the intedenkin-2 and interferon-γ cDNAs. Blood 83(5): 1289-1298, 1994.
66. Gansbacher B, Rosenthal FM, Zier K: Retroviml vector-mediated cytokine-gene transfer into tumor cells. Cancer Invest 11(3):35-354, 1993.
67. Allione A, Consalvo M, Nnani P, et al: Immuniziug and curdtive potential of replicating and nonreplicatin routine mmumary adenocarcinoma cells engineered with intericuifin (IL-2, IL-6, IL-7, IL-10, tumor necrosis factor ∞, granulocyte-macrophage colony-stimulating factor, and γ-interferon gnne or admined with convenfional adjuvants. Cancer Res 54:6022-6026, 1994.
68. Rosinberg SA, Anderson WF, Blaese MR, et al: Immunization of cancer petients using autolognus cancer cells modifiod by insertion of the gene for interleukin-2. Hum Gene Ther 3:75-90, 1992.
69. Taylor-Papadimitriou J, D'Souza B, Burchell J, et al: The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. Ann NY Acad Sci Nov 30:31-47, 1993.
70. Hareuveni M, Gautier C, Kieny ME et al: Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA 87:9498-9502, 1990.
71. Bu D, Domenech N, Lewis J, et al: Recombinant vaccinia mucin vector: in vitro analysis of expression of tumor-associated epitopes for antibody and human cytotoxic T cell recognition. J Immunother 14:127-135, 1993.
72. Acres RB, Hareuveni M, Balloul JM, et al: Vaccinia virus MUC1 immunization of mice: Immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunother 14:136-143, 1993.
73. Ding L, Lalani EN, Reddi M, et al: Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenucarcinoma cells transfected with the human MUC1 gone. Cancer Immunol Immunother 36:9-17, 1993.
74. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676-1680, 1988.
75. Rosenberg SA, Spiess P, Lafreniere RA: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986.
76. Chang AE, Yobizawa H, Saltai K, et al: Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53:1043-1050, 1993.
77. Schwartzentruber DJ, Solomon D, Rosenberg SA, et al: Characterization of lymphocytes infiltrating human breast cancer: Specific immune reactivity detected by measuring cytokine secretion. J Immonother 12:1-12, 1992.
78. Rubbert A, Manger B, Lang N, et al: Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocy and peripheral-blood lymphocytes from petient with breast cancer. Int J Cencer 49:25-31, 1991.
79. Jerome KR, Barnd DL, Bendt KM, et al: Cytotoxic T-lymphocytes derived from patients with breast ndenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51:2908-2916, 1991.
80. Disis ML, Calenoff E, McLaughlin G, et al: Existent T-cell and antibody immunity to HER-2/neu protein in petients with breast cancer. Cancer Res 54:16-20, 1994.
81. Peoples GE, Davey MP, Goedegebuure PS, et al: T cell receptor Vβ6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 151(15):5472-5480, 1993.
82. + ovarian cancers. J Immunol 152:4993-4999, 1994.
83. Yohino I, Peoples GE, Goedegebuure PS, et al: Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152:2393-2400, 1994.
84. Peoples GE, Goedegebuure PS, Smith R, et al: Breast and ovarian cancer-specific cytotoxic T lymhocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436, 1995.
85. Jerome KR, Domenech N, Finn OJ: Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells tramfacted with polymorphic epithelial mucin complementary DNA. J Immunol 151(3):1654-1662, 1993.
86. Stancovski I, Schindler DG, Waks T, et al: Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptor. J Immunol 151(11):6577-6582, 1993.
87. Nagler A, Morecki S, Ackerstein A, et al: In: Experimental and Clinical Cellular Immunotherapy in Bone Marrow Transplantation, edited by G Morstyn, WP Sheridan, 1995 (in press).